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Abstract 
Background: Centipeda minima (Ebushicao) has been used for the treatment of various diseases, such as nasal 
allergies, rhinitis and sinusitis, nasopharyngeal carcinoma, cough, and headache. This study aims to investigate the 
anticancer activities of Centipeda minima ethanol extracts (CME) against nasopharyngeal carcinoma cell CNE‑1 and 
their underlying mechanism.
Methods: CNE‑1 cells were treated with different concentrations (15–50 μg/mL) of CME for different time intervals 
(24, 48, and 72 h). Cytotoxicity of CME was determined by MTT assay. Cell morphological changes were observed by 
fluorescence microscopy after HO 33258 staining. Cell cycle status was evaluated by flow cytometry following pro‑
pidium iodide staining. Apoptosis was detected by flow cytometry following annexin V‑FITC/PI staining. The levels of 
apoptosis‑associated and PI3K‑Akt‑mTOR signaling related proteins were measured by western blotting analysis.
Results: CME (15–50 μg/mL) significantly inhibited the proliferation of CNE‑1 in a dose‑ and time‑dependent 
manner (P = 0.026 for 15 μg/mL, P < 0.001 for 25, 30, 40, and 50 μg/mL, respectively); the IC50 values (μg/mL) were 
41.57 ± 0.17, 30.34 ± 0.06 and 24.98 ± 0.08 for 24, 48 and 72 h treatments, respectively. Significant morphologi‑
cal changes of CNE‑1 cells displaying apoptosis were observed after CME treatment. CME showed low cytotoxicity 
toward normal LO2 cells. CNE‑1 cells were arrested in the G2/M phase while treated with 15, 25, 40 μg/mL of CME, 
respectively (P = 0.032, P = 0.0053, P < 0.001). CME (15, 25, 40 μg/mL) down‑regulated Bcl‑2 expression (P = 0.032, 
P = 0.0074, P < 0.001), and up‑regulated Bax (P = 0.026, P = 0.0056, P < 0.001) with activation of caspase‑3, caspase‑8, 
caspase‑9, and PARP observed in CNE‑1 cells (P = 0.015, P = 0.0067, P < 0.001 for caspase 3; P = 0.210, 0.028, < 0.001 
for caspase 8; P = 0.152, 0.082, 0.0080 for caspase 9; P = 0.265, 0.0072, < 0.001 for PARP). CME suppressed the acti‑
vation of the PI3K‑AKT‑mTOR pathway (P = 0.03, 0.0007, 0.004, 0.006, 0.022 for p‑PI3K, p‑Akt‑Ser473, p‑Akt‑Thr308, 
p‑mTOR‑Ser2448, p‑mTOR‑Ser2481, respectively after 40 μg/mL of CME treated for 24 h).
Conclusion: CME inhibited the proliferation of CNE‑1 cells and activation of the PI3K‑AKT‑mTOR signaling pathway.
© 2015 Guo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nasopharyngeal carcinoma (NPC), a malignant epi-
thelial tumor derived from the nasopharyngeal surface 
epithelium, has a low incidence in Western countries 
but a high incidence in Southeast Asia, southern China 
and the Mediterranean basin [1]. Epstein-Barr virus 
infection is a critical factor in NPC pathogenesis [2, 3]. 
Additional etiological factors for NPC include genetic 
susceptibility, environmental contamination, and dietary 
habits such as excessive consumption of salt-preserved 
fish during childhood [1, 4]. Radiotherapy is the stand-
ard primary treatment for NPC [5], and a combination 
of radiotherapy and chemotherapy has been shown to be 
an effective therapeutic strategy for treating advanced 
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NPC [6]. The most prevalent chemotherapeutic drugs 
used to treat NPC are cisplatin-based drugs, which are 
highly toxic and prone to drug resistance [7, 8]. Chinese 
medicine (CM) in combination with conventional can-
cer therapies has been applied to NPC [9]. Controlled 
clinic trials demonstrated that CM therapies achieve 
prolonged survival and improved quality of life in NPC 
patients [10, 11].
Some CMs exhibit antitumor activities toward NPC 
cells via growth inhibition, apoptotic induction and 
cell cycle arrest [12, 13]. Centipeda minima (L.) A. et 
Aschers. (Ebushicao) (Asteraceae) has been used to treat 
nasal allergies, rhinitis, sinusitis, cough, headache [14, 
15] and NPC [16]. Recent researches have focused on its 
anti-NPC activities, leading to the isolation of a few ses-
quiterpene lactones against NPC cells [17, 18]. Volatile 
oils from C. minima extracted by steam distillation and 
supercritical fluid extraction induced CNE cell death via 
induction of intrinsic apoptosis by regulating the expres-
sion of the Bcl-2 family of proteins [16]. Ethyl acetate 
extracts of C. minima exhibited anti-proliferative activity 
against CNE-2 cells [19]. However, the anticancer activi-
ties of C. minima ethanol extracts (CME) against the 
NPC cell line CNE-1, and their underlying mechanism, 
remain unclear.
This study aims to investigate the anticancer activities 
of CME against the nasopharyngeal carcinoma cell line 
CNE-1 and determine their underlying mechanism.
Methods
Plant materials and sample preparation
Centipeda minima was collected in August 2010 in 
Xiangfan, Hubei Province, China (latitude, 32°04′ N; 
longitude, 112°05′ E), and authenticated by Si-bao Chen 
based on morphological features. A voucher specimen 
(EBSC-016-09) was deposited at the herbarium of the 
State Key Laboratory of Chinese Medicine and Molecu-
lar Pharmacology, Department of Applied Biology and 
Chemical Technology, The Hong Kong Polytechnic Uni-
versity. The herb was air-dried and ground to coarse 
powder. The powder (30 g) was macerated with 0.5 L of 
95 % ethanol at room temperature for 72 h. The extrac-
tion was repeated twice. After extraction, the ethanol 
extracts were combined, filtered through Whatman fil-
ter paper (Whatman, Maidstone, UK), and evaporated 
to dryness using a rotary evaporator (Precision MLG3, 
Heidolph, Germany) on a water bath at 40  °C, and fur-
ther lyophilized to dried powder (3.80 g). CME samples 
with a yield of 12.65 % were stored in the refrigerator at 
4 °C until further use. CME was dissolved in DMSO and 
filtered to 0.22 μm to obtain the stock concentration of 
20  mg/mL. Finally, a serial dilution to concentrations 
of 15, 25, 30, 40, and 50  μg/mL CME was performed. 




mide (MTT), dimethyl sulfoxide (DMSO), Hoechst 33258 
and cisplatin were obtained from Sigma (St. Louis, MO, 
USA). The annexin V-FITC apoptosis detection kit and cell 
cycle analysis kit were purchased from Beyotime (Invitro-
gen, Carlsbad, CA, USA). Precision Plus Protein Standards 
(Dual Color) and Immun-Star™ WesternC™ Chemilumi-
nescent Kit were purchased from Bio-Rad (Hercules, CA, 
USA). Antibodies against procaspase 8, cleaved caspase 9, 
cleaved PARP, PI3K p110α, Akt, p-Akt (Thr308 and Ser473), 
mTOR and p-mTOR (Ser2448 and Ser2481) were obtained 
from Cell Signaling Technology (Beverly, MA, USA). All 
other primary antibodies, as well as anti-rabbit and anti-
mouse secondary horseradish peroxidase antibodies, were 
purchased from Abcam (Cambridge, MA, USA). All other 
common chemicals were reagent grade.
Cell culture
CNE-1 human nasopharyngeal carcinoma cells (deposi-
tory no. CBP60002) were purchased from the Cancer 
Institute and Hospital, Chinese Academy of Medical 
Sciences (Beijing, China). LO2 human normal liver cells 
(depository no. GNHu 6) were purchased from the Cell 
Bank of Chinese Academy of Sciences (Shanghai, China). 
Cells were cultured in RPMI-1640 medium (Invitrogen, 
USA) supplemented with 10 % fetal bovine serum (Gibco, 
Life Technologies, Grand Island, NY, USA), 100  IU/
mL penicillin, 100 μg/mL streptomycin (Thermo Fisher 
Scientific, Madison, WI, USA) at 37  °C in a humidified 
incubator with a 5 % CO2 atmosphere. The medium was 
renewed three times a week. Cells in logarithmic growth 
phase were used for all experiments.
Cell viability assay
The effects of CME on the viability of CNE-1 and LO2 
cells were evaluated by MTT assay [20]. Cells (3 ×  104 
cells/mL) were seeded into the wells of 96-well culture 
plates (Thermo Fisher Scientific) in 100 μL of medium 
per well and then allowed to adhere for 24  h at 37  °C 
in a 5  % CO2 atmosphere. After incubation, the cells 
were treated with the target concentrations of CME 
(15–50 μg/mL), 0.1 % DMSO as the vehicle control, and 
cisplatin (4 μg/mL) as a positive control, for 24 h. After 
incubation for 24, 48, and 72 h at 37 °C in a CO2 incuba-
tor, 10 μL of MTT solution [5 mg/mL in phosphate-buff-
ered saline (PBS)] was added to each well and incubated 
for a further 4 h. Then, excess medium was removed and 
150 μL of DMSO was added to each well to dissolve the 
formazan crystals. The optical density in each well was 
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measured using a microplate spectrophotometer (BMG 
POLARstar Galaxy, Offenburg, Germany) at 490  nm. 
Triplicate experiments were performed for treatment 
with each concentration. The percentage cell viability 
(%) was calculated by comparison with a sample’s corre-
sponding control. IC50 values were calculated to evaluate 
the cytotoxic effects of treatments on CNE-1 cells.
Morphological assessment
The cells (1  ×  106 cells/mL) were seeded into 6-well 
plates, and then treated with different concentrations (15, 
25, 30, 40, or 50 μg/mL) of CME for 24 h. Similarly, cells 
were treated with 25 μg/mL CME for 24, 48, and 72  h, 
respectively. DMSO (0.1 %)-treated cells were employed 
as controls. Subsequently, the cells were washed twice 
with cold PBS, fixed with 4 % paraformaldehyde solution 
for 10 min, stained with Hoechst 33258 (10 μg/mL) for 
15 min in the dark, and then observed under an inverted 
fluorescence microscope (Leica DMRB, Weitzl, Ger-
many) at the excitation wavelength of 352 nm and emis-
sion wavelength of 461 nm.
Apoptosis analysis by annexin V‑FITC/PI staining
The numbers of apoptotic cells were assessed using an 
annexin V-FITC apoptosis detection kit (Invitrogen, 
USA) according to the manufacturer’s protocol. Cells 
(1 × 106 cells/mL) were treated with various concentra-
tions of CME for 24, 48, and 72 h. Cells were then har-
vested, and re-suspended in binding buffer. Subsequently, 
cells were stained with 5 mL of annexin V-FITC and 5 mL 
of propidium iodide (PI) for 15 min at room temperature 
in the dark. The apoptotic cell percentages were then 
immediately detected using a FACSCalibur flow cytom-
eter (BD Biosciences, San Jose, CA, USA).
Cell cycle analysis by PI staining
Cells (1 × 106 cells/well) were treated with various con-
centrations of CME (15, 25, and 40  μg/mL) for 24, 48, 
and 72  h. Cells were then collected and washed twice 
with 1 mL of ice-cold PBS, suspended in 1 mL of ice-cold 
70  % ethanol (containing 1  ×  105 cells) and kept over-
night at 4  °C. The next day, cells were washed with PBS 
and incubated with 500 μL of PI staining solution (con-
taining PI 40 μg/mL, RNase A 100 μg/mL and PBS) for 
30 min in the dark at 37 °C. Then, samples were filtered 
using 70-μm filters into test tubes and detected by flow 
cytometry (FACSCalibur, Bio-Rad). Analysis of cell cycle 
status was performed using ModFit LT 3.0™ software 
(BD Biosciences).
Western blot analysis
CNE-1 cells (1 ×  106 cells/well) were seeded into 100  mL 
culture dishes for 24  h and then treated with various 
concentrations of CME (15, 25, and 40 μg/mL). After incu-
bation for 24  h, the cells were harvested and prepared in 
NP-40 lysis buffer (2  mM Tris–Cl pH 7.5, 150  mM NaCl, 
10 % glycerol and 0.2 % NP-40 plus a protease inhibitor cock-
tail) for 30  min on ice. Cell lysates were ultra-centrifuged 
(Allegra™ 21R Centrifuge, Beckman Coulter, Krefeld, Ger-
many) at 14,000×g for 10 min at 4 °C, and then the super-
natant was collected as the total cellular proteins. Protein 
concentrations were determined using a BCA protein assay 
kit (Beijing ComWin Biotech Co.,Ltd., Beijing, China). Pro-
teins (10 μg for β-actin and Bax, 20 μg for PARP and cleaved 
PARP, 30 μg for caspase-3, -9, and -8, PI3K p110α, Akt, and 
p-Akt, 50 μg for Bcl-2, mTOR, and p-mTOR) were resolved 
on 12–15 % SDS-PAGE gels, then transferred to PVDF (pol-
yvinylidene difluoride) membranes (Roche Applied Science, 
Basel, Switzerland) and blocked with 5 % non-fat dry milk 
in Tris-buffered saline containing 0.1 % Tween-20 (T-TBS) 
overnight at 4 °C. After washing with T-TBS, the membranes 
were incubated with primary antibodies against procas-
pase-3, -8, and -9; caspase-3, -8, and -9; Bcl-2, Bax, PARP, 
cleaved PARP; PI3K p110α, Akt, p-Akt (Thr308 and Ser473), 
mTOR, p-mTOR (Ser2448 and Ser2481), and β-actin over-
night at 4  °C. Subsequently, the membranes was incubated 
with goat anti-rabbit or horseradish peroxidase-conjugated 
goat anti-rabbit secondary antibodies (Merck Millipore) at 
room temperature for 2 h at dilutions of 1:5000 and 1:10,000, 
respectively. Antibody-bound proteins were detected, nor-
malized to β-actin and quantified in a ChemiDoc™ XRS 
system (Universal Hood II, Bio-Rad) using an Immun-Star™ 
HRP Chemiluminescence Kit (Bio-Rad).
Statistical analysis
All data are expressed as the mean ± standard deviation 
(SD) of at least three independent experiments. Analy-
ses of dose-, concentration- and time-dependent effects 
were performed by sigmoidal non-linear regression using 
GraphPad Prism 5.02 software (GraphPad Software, Inc., 
La Jolla, CA, USA). The percentage cell viability (%) after 
CME treatment with different concentrations and time 
intervals was used for the fitting. The two-tailed Student’s 
t test was used for comparisons of two groups, and multi-
group differences were analyzed by one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple com-
parison test. P values < 0.05, 0.01, or 0.001 were consid-
ered statistically significant.
Results
Cytotoxic effects of CME on CNE‑1 cells
CNE-1 cells were treated with various concentrations 
(15–50 μg/mL) of CME for 24, 48, and 72 h, and the cell 
viability was determined by MTT assay. CME decreased 
CNE-1 cell viability in a dose- and time-dependent man-
ner (Fig. 1; Table 1). After treatment with CME (15, 25, 30, 
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40 and 50 μg/mL) for 24 h, the percentage of live cells were 
95.41, 81.27, 60.10, 50.0 and 42.41 %, (P = 0.026 for 15 μg/
mL, P < 0.001 for 25, 30, 40, and 50 μg/mL), respectively. 
Meanwhile, those were 51.14, 34.0, and 25.05 % (P < 0.001 
for each test), while CNE-1 cells were treated with CME 
(40 μg/mL) for 24, 48, and 72 h, respectively. The IC50 val-
ues were 41.57 ± 0.17, 30.34 ± 0.06 and 24.98 ± 0.08 μg/
mL for 24, 48, and 72 h incubations, respectively. Despite 
its potency in CNE-1 cells, CME exhibited no significant 
cytotoxic effect on normal LO2 cells (data not shown due 
to no significant variation versus vehicle control).
Morphological changes in CNE‑1 cells after CME treatment
Morphological changes and cell death in CNE-1 cells 
were observed under an inverted fluorescence micro-
scope (DFC 420 C, Leica, Germany) after HO 33258 
staining. Vehicle-treated (control) cells showed normal 
cell architecture with clear cytoskeletons (Fig. 2). Typical 
morphological changes associated with apoptosis, includ-
ing chromatin condensation, apoptotic body formation 
and nuclear degradation, were observed in CME-treated 
cells. These morphological changes were enhanced with 
increasing concentrations of CME (Fig.  2a), and with 
increasing treatment duration (Fig. 2b).
Apoptosis analysis by flow cytometry
The timing of induction of apoptosis was determined 
by flow cytometry following annexin V-FITC/PI double 
staining. After exposure to CME (15, 25, or 40 μg/mL) 
for 48  h, the proportion of apoptotic cells dramatically 
increased in a dose-dependent manner; the percentages 
of apoptotic cells were 39.53, 56.43, and 76.42 %, respec-
tively (P = 0.0086, P < 0.001, P < 0.001) (Fig. 3a). Similarly, 
Fig. 1 Dose‑ and time‑dependent cytotoxic effects of CME on CNE‑1 cells. CNE‑1 cells were treated with 0.1 % DMSO (vehicle control), 4 μg/mL 
cisplatin (positive control) and various concentrations (15–50 μg/mL) of CME for 24, 48, and 72 h, respectively, and then cell viability was deter‑
mined by MTT assay. Values are the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.001 versus control
Table 1 The P value of significance analysis in each experi-




15 25 30 40 50
24 0.032 0.0006 0.0005 0.0007 0.0006
48 0.0009 0.0008 0.0004 0.0005 0.0002
72 0.0007 0.0002 0.0006 0.0003 0.0001
Fig. 2 Cell morphological changes induced by CME. a Cells treated 
with various concentrations of CME (15, 25, 30, 40, and 50 μg/mL) 
for 24 h. b Cells treated with 25 μg/mL for 24, 48, and 72 h. The cells 
were fixed after CME treatment, stained with HO 33258, and their 
nuclear morphology was photographed under fluorescence using a 
blue filter (×400). The arrow points to an apoptotic body
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CME induced CNE-1 cell apoptosis in a time-dependent 
manner. The percentages of apoptotic cells were 43.30, 
76.42, and 91.29 % after treatment with 40 μg/mL CME 
for 24, 48, and 72 h, respectively (P < 0.001 for each test) 
(Fig. 3b).
Flow cytometric analysis of the cell cycle status of CNE‑1 
cells
Cell cycle progression was analyzed by flow cytome-
try to determine whether the cytotoxic effect of CME 
toward CNE-1 cells was associated with the induc-
tion of cell cycle arrest. After treatment with 15, 25, 
and 40 μg/mL CME for 48 h, the percentages of cells 
in the G2/M phase were 16.00, 24.71, and 60.85  %, 
respectively (P =  0.032, P =  0.0052, P < 0.001); while 
the percentages of those in the G0/G1 phase were 
50.74, 47.67, and 21.94  %, respectively (P  =  0.102, 
0.067, P < 0.001) (Fig. 4a). Meanwhile, after treatment 
with CME (40  μg/mL) for 24, 48, and 72  h, the per-
centages of cells in the G2/M phase were 29.38, 35.21, 
and 41.13 %, respectively (P < 0.001 in each test); while 
the percentages of those in the G0/G1 phase were 
42.69, 30.20, and 25.64  %, respectively (P  =  0.0072, 
P  =  0.0047, P  <  0.001) (Fig.  4b). No significant vari-
ations in the percentages of cells in S phase were 
observed after CME treatment. These results indicated 
that the inhibition of CNE-1 cell proliferation induced 
by CME could be attributed to cell cycle arrest in the 
G2/M phase.
Expression of CME‑regulated apoptosis‑related proteins
The expression levels of apoptosis-related proteins were 
analyzed by western blotting to study CME-induced apop-
tosis of CNE-1 cells in more detail. After treatment with 
CME (15, 25, 40 μg/mL) for 24 h, the levels of cleaved cas-
pase 3, 8, 9 and cleaved PARP increased in a dose-depend-
ent manner (P = 0.020, P = 0.0060, P < 0.001 for caspase 
3; P = 0.210, 0.028, < 0.001 for caspase 8; P = 0.152, 0.082, 
0.0082 for caspase 9; P = 0.265, P = 0.0060, P < 0.001 for 
PARP), while the levels of pro-caspases 3, 8, 9 and PARP 
decreased (P = 0.0045, P < 0.001, P < 0.001 for pro-caspase 
3; P  =  0.147, 0.015, 0.036 for pro-caspase 8; P  =  0.250, 
0.031, 0.0085 for pro-caspase 9; P = 0.092, < 0.001, 0.001 
for pro-PARP) (Fig.  5a). Meanwhile, the anti-apoptotic 
protein Bcl-2 was down-regulated (P = 0.035, P = 0.0055, 
P  <  0.001), while the pro-apoptotic protein Bax was up-
regulated (P = 0.020, P = 0.0035, P < 0.001) (Fig. 5b), and 
the Bax/Bcl-2 ratio was significantly increased as the con-
centrations of CME increasing (P =  0.072, 0.034, 0.0005) 
(Fig. 5c).
Inhibition of PI3K‑Akt‑mTOR signaling in CME‑treated 
CNE‑1 cells
We investigated whether CME treatment could also 
down-regulate the expression levels of related proteins 
in the PI3K-Akt-mTOR pathway. After treatment with 
CME (15, 25, 40 μg/mL) for 24 h, the levels of PI3Kinase 
P110α, the catalytic subunit of PI3K (P  =  0.042, 0.040, 
0.030), and the amount of phosphorylation of Akt at 
Fig. 3 Flow cytometry analysis of the induction of apoptosis in CNE‑1 cells by CME. Results are shown in logarithmic fluorescence intensity with the 
x‑axis (annexin V‑FITC) versus y axis (PI). Four quadrants represent necrotic cells (Q1: AV−/PI+), late apoptotic cells (Q2: AV+/PI+), early apoptotic cells 
(Q3: AV+/PI−) and viable cells (Q4: AV−/PI−). Numbers indicate the percentages of cells in each quadrant and a minimum of 5000 events were read 
(n = 3). a CNE‑1 cells were treated with 15, 25, and 40 μg/mL CME for 48 h; b CNE‑1 cells were treated with 40 μg/mL CME for 24, 48, and 72 h
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Fig. 4 Cell cycle distribution of CNE‑1 cells in the flow cytometric analysis after CME treatment. a CNE‑1 cells were treated with 0.1 % DMSO (con‑
trol) and 15, 25, and 40 μg/mL CME for 48 h; b CNE‑1 cells were treated with 40 μg/mL CME for 0 (control), 24, 48, and 72 h
Fig. 5 Effects of CME on the expression levels of apoptosis‑related proteins in CNE‑1 cells after 24 h of treatment. a Expression levels of procas‑
pase‑3, ‑8, and ‑9; caspase‑3, ‑8, and ‑9; PARP and cleaved‑PARP. b Expression level of Bcl‑2 and Bax. c Bax/Bcl‑2 ratios; each value is based on three 
independent experiments. *P = 0.034, **P = 0.0005 versus control
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Ser473 (P = 0.047, 0.0008, 0.0007) and Thr308 (P = 0.021, 
0.005, 0.004) were remarkably decreased in a concentra-
tion-dependent manner, while the amount of total Akt 
remained constant following CME treatment (Fig.  6). 
Consistently, phosphorylation of the downstream effec-
tor mTOR at Ser2448 (P = 0.037, 0.025, 0.006) and Ser2481 
(P = 0.046, 0.039, 0.022) also showed a dose-dependent 
decrease, and the amount of total mTOR was slightly 
down-regulated upon CME treatment of CNE-1 cells.
Discussion
In the present study, the anti-cancer effects of CME 
toward human nasopharyngeal carcinoma CNE-1 cells in 
terms of cytotoxicity, apoptosis induction and cell cycle 
arrest were investigated. CME possessed significant cyto-
toxic activities against CNE-1 cells, in a time- and dose-
dependent manner, but very low cytotoxicity toward 
normal LO2 cells. These results suggest that CME has 
potential selective anti-cancer effects on CNE-1 cells.
Apoptotic induction in cancer cells is a crucial thera-
peutic strategy for cancer treatment. CME induced 
morphological changes including cell shrinkage, the 
appearance of apoptotic vacuoles, and chromatin con-
densation, detected by fluorescence microscopy after 
CME treatment followed by Ho 35288 staining. This 
apoptotic induction was confirmed by flow cytometry 
using an annexin V-FITC/PI double-staining approach.
In this study, changes in cell cycle progression were 
analyzed by flow cytometry. CME induced obvious G2/M 
phase arrest in CNE-1 cells in a dose- and time-depend-
ent manner. G2/M, the most important checkpoint for 
DNA damage, is critical to cell cycle progression, and 
strictly regulated by specific genes [21]. If phase arrest 
cannot be repaired, cells may undergo apoptosis.
Changes in the expression levels of apoptosis-related 
proteins in CNE-1 cells after CME treatment were eval-
uated by western blotting to explore the mechanism 
underlying the induction of apoptosis by CME in CNE-1 
cells. The activation of caspase 9 through apoptotic pro-
tease activating factor-1 (APAF-1) and cytochrome c 
release [22] initiates activation of the caspase cascade, 
cleaves executioner caspase-3, and eventually results in 
apoptosis [23]. Cleaved caspase 8 activates downstream 
caspases such as caspase-3, -6, and -7 [24], which cleave 
specific intracellular substrates, such as polyADP-ribose 
polymerase (PARP), lamins and inhibitor of caspase acti-
vated DNase (ICAD), finally resulting in programmed 
cell death [25]. This study revealed that CME could sig-
nificantly induce CNE-1 cell apoptosis via the activation 
of caspase-8, -9, -3, as well as PARP, through both extrin-
sic and intrinsic pathways.
The B cell lymphoma 2 (Bcl-2) family proteins, includ-
ing pro-apoptotic members such as Bax, Bak and anti-
apoptotic members such as Bcl-2, Bcl-xL, play important 
roles in the regulation of mitochondrial-mediated apopto-
sis [26, 27]. In this study, CME treatments downregulated 
the expression of Bcl-2, and upregulated the expression 
of Bax, resulting in CNE-1 cell apoptosis. Furthermore, 
elevated intracellular ratios of Bax/Bcl-2 were observed 
during a period of increased apoptotic cell death. These 
experimental findings suggested that CME induced 
CNE-1 cell apoptosis via a mitochondrial pathway.
The PI3K-AKT-mTOR pathway is a major signal-
ing pathway in cancer [28]. This pathway is frequently 
mutated and overactivated in human cancers [29]. The 
PI3K-AKT-mTOR pathway promotes survival through 
inhibition of proapoptotic factors and activation of 
anti-apoptotic factors [30]. Through phosphoryla-
tion of pathway components, this pathway inhibits the 
activity of proapoptotic members while activating anti-
apoptotic members [31]. Therefore, blockade of the 
PI3K-AKT-mTOR pathway has become a cancer ther-
apy strategy. Our present results indicate for the first 
time that CME downregulates the PI3K-AKT-mTOR-
mediated signaling in CNE-1 cells (Fig. 7). Additionally, 
14-thienyl methylene matrine (YYJ18), a derivative of 
matrine, has been reported to induce apoptosis in NPC 
cells by targeting PI3K-Akt [32], which also provides 
evidence for the involvement of this pathway in NPC 
carcinogenesis.
Fig. 6 Inhibition of the PI3K‑Akt‑mTOR signaling pathway in CNE‑1 
cells by CME. After treatment with the indicated concentrations of 
CME for 24 h, cell lysates were subjected to western blot analysis 
using the indicated antibodies against PI3K p110α, Akt and p‑Akt 
(Thr308 and Ser473), mTOR and p‑mTOR (Ser2448 and Ser2481). β‑actin 
served as a loading control
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Conclusion
CME inhibited the proliferation of CNE-1 cells and acti-
vation of the PI3K-AKT-mTOR signaling pathway.
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